Last reviewed 2026-04-23 · How we verify

Metformin 1500mg, QD

Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I.

Metformin reduces hepatic glucose production and improves insulin sensitivity by activating AMP-activated protein kinase (AMPK) and inhibiting mitochondrial complex I. Used for Type 2 diabetes mellitus.

At a glance

Mechanism of action

Metformin decreases gluconeogenesis in the liver and enhances peripheral glucose uptake and utilization, primarily through AMPK activation. It also improves insulin sensitivity and may have modest effects on gastrointestinal glucose absorption. The drug does not stimulate insulin secretion, making it weight-neutral and suitable for use across a broad range of glucose levels.

Approved indications

• Type 2 diabetes mellitus

Common side effects

• Gastrointestinal disturbance (nausea, diarrhea, abdominal discomfort)
• Metallic taste
• Vitamin B12 deficiency
• Lactic acidosis (rare)

Key clinical trials

• Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility (PHASE3)
• Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3) (PHASE3)
• Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Metformin 1500mg, QD CI brief — competitive landscape report
• Metformin 1500mg, QD updates RSS · CI watch RSS
• Daewoong Pharmaceutical Co. LTD. portfolio CI